Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Policy update increases access for millions covered by HCSC BlueCross BlueShield policiesMALVERN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics,...
Neuroscience
Sensus Healthcare Sells SRT System to Providence Swedish Hospital
Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla., Sept. 25, 2024...
FONDAZIONE PRADA PRESENTS “PRESERVING THE BRAIN: A CALL TO ACTION” IN MILAN
MILAN, Sept. 25, 2024 /PRNewswire/ -- The new edition of "Preserving the Brain," part of Fondazione Prada's "Human Brains" project...
BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING
MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing...
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower...
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific...
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver...
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with DepressionMALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE)...
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA...
Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor
Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September...
ONWARD® Medical Announces Third Implant of Brain-Computer Interface (BCI) System to Restore Movement after Spinal Cord Injury
Company continues pioneering research on BCI-enabled system to restore mobility after spinal cord injuryEINDHOVEN, The Netherlands, Sept. 19, 2024 (GLOBE...
TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide
New messaging reflects TFS's commitment to patient-centered clinical research and global partnerships LUND, Sweden, Sept. 19, 2024 /PRNewswire/ -- TFS HealthScience...
MIT xPRO Launches the Medical Technology Program for Global Leaders in Collaboration with Emeritus
This seven-month online program is designed to help senior medtech executives step up to a C-suite role and create value...
Neurohacker Announces Name Change To Qualia Life Sciences As Part Of Expansion
CARLSBAD, Calif., Sept. 18, 2024 /PRNewswire/ -- The pioneering health and wellness brand formerly known as Neurohacker Collective, has recently completed...
Flourish Research Announces Strategic Majority Investment from Genstar Capital
Investment to bolster leading multi-site clinical trial organization to further scale across therapeutic areas and geographies APEX, N.C. and SAN...
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50...